Table S1 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma

Table S1 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma

<p>Supplementary Table S1: Genomic and clinical characteristics of the study cohort.</p>

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Ryan D. Chow (15109654) (author)
مؤلفون آخرون:	Tai Michaels (15122331) (author), Stefania Bellone (15122334) (author), Tobias M.P. Hartwich (15122337) (author), Elena Bonazzoli (15122340) (author), Akiko Iwasaki (15122343) (author), Eric Song (15122346) (author), Alessandro D. Santin (15122349) (author)
منشور في:	2025
الموضوعات:	Cancer Therapeutic Research and Development Immuno-oncology Gynecological Cancers Endometrial cancer Immunotherapy Translational Research
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة

Table S2 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma
حسب: Ryan D. Chow (15109654)
منشور في: (2025)

Table S3 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma
حسب: Ryan D. Chow (15109654)
منشور في: (2025)

Table S4 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma
حسب: Ryan D. Chow (15109654)
منشور في: (2025)

Supplemental Table 1 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
حسب: Zannel Blanchard (16617018)
منشور في: (2025)

Supplemental Table 2 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
حسب: Zannel Blanchard (16617018)
منشور في: (2025)

Supplemental Table 3 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
حسب: Zannel Blanchard (16617018)
منشور في: (2025)

Figure 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
حسب: Niccolò G. Santin (22229756)
منشور في: (2025)

Figure 2 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
حسب: Niccolò G. Santin (22229756)
منشور في: (2025)

Figure 3 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
حسب: Niccolò G. Santin (22229756)
منشور في: (2025)

Figure 4 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
حسب: Niccolò G. Santin (22229756)
منشور في: (2025)

Figure 5 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
حسب: Niccolò G. Santin (22229756)
منشور في: (2025)

Table 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
حسب: Niccolò G. Santin (22229756)
منشور في: (2025)

Supplemental Figure 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
حسب: Niccolò G. Santin (22229756)
منشور في: (2025)

Supplemental Figure 2 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
حسب: Niccolò G. Santin (22229756)
منشور في: (2025)

Table 2_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.xlsx
حسب: Yumeng Cai (5591276)
منشور في: (2025)

Table 1_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.xlsx
حسب: Yumeng Cai (5591276)
منشور في: (2025)

Image 1_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
حسب: Yumeng Cai (5591276)
منشور في: (2025)

Table 3_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.docx
حسب: Yumeng Cai (5591276)
منشور في: (2025)

Image 3_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
حسب: Yumeng Cai (5591276)
منشور في: (2025)

Image 2_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
حسب: Yumeng Cai (5591276)
منشور في: (2025)

Image 5_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.jpg
حسب: Yumeng Cai (5591276)
منشور في: (2025)

Image 4_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
حسب: Yumeng Cai (5591276)
منشور في: (2025)

Image 6_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
حسب: Yumeng Cai (5591276)
منشور في: (2025)

Image 7_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tiff
حسب: Yumeng Cai (5591276)
منشور في: (2025)

Table 1_Evaluation of microsatellite instability patterns in mismatch repair deficiency: a retrospective analysis of 285 endometrial cancers.docx
حسب: Cheng Wang (102692)
منشور في: (2025)

Supplementary Figure 1 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
حسب: Shigehiro Yagishita (15088446)
منشور في: (2025)

Supplementary Figure 2 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
حسب: Shigehiro Yagishita (15088446)
منشور في: (2025)

Supplementary Figure 3 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
حسب: Shigehiro Yagishita (15088446)
منشور في: (2025)

Supplementary Figure 4 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
حسب: Shigehiro Yagishita (15088446)
منشور في: (2025)

Supplementary Table S4 from Evolution and Co-occurrence of PI3K Pathway Gene Mutations in Endometrial Carcinoma Molecular Subtypes at the Single-Cell Level
حسب: Arnaud Da Cruz Paula (17316230)
منشور في: (2025)

Immune checkpoint inhibitors or targeted therapy by mismatch repair status in endometrial cancer: a meta-analysis
حسب: Yi Tang (55726)
منشور في: (2025)

Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
حسب: Martina S.J. McDermott (15206951)
منشور في: (2025)

Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
حسب: Martina S.J. McDermott (15206951)
منشور في: (2025)

Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
حسب: Martina S.J. McDermott (15206951)
منشور في: (2025)

Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
حسب: Martina S.J. McDermott (15206951)
منشور في: (2025)

Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
حسب: Martina S.J. McDermott (15206951)
منشور في: (2025)

Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
حسب: Martina S.J. McDermott (15206951)
منشور في: (2025)

Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
حسب: Martina S.J. McDermott (15206951)
منشور في: (2025)

Figure S8 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
حسب: Martina S.J. McDermott (15206951)
منشور في: (2025)

Supplemental Tables 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
حسب: Martina S.J. McDermott (15206951)
منشور في: (2025)